-
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
08 Jan 2025 12:30 GMT
… of this important medical countermeasure to … franchise includes two treatments, Anthrasil® [Anthrax … raxibacumab, a monoclonal antibody therapeutic. About BioThrax® (Anthrax Vaccine … manufacturing services for pharmaceutical and biotechnology customers. To …
-
Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)
16 Dec 2024 13:00 GMT
… vaccine was approved by the U.S. Food & Drug Administration (FDA … antibody therapeutic, and raxibacumab, a monoclonal antibody … the vaccine. Allergic reactions: Appropriate medical treatment and … services for pharmaceutical and biotechnology customers. To …
-
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
20 Jul 2023 22:03 GMT
… raxibacumab, a monoclonal antibody therapeutic. The FDA approval of CYFENDUS™ vaccine … the vaccine and antibacterial drugs approved … the vaccine. Allergic reactions: Appropriate medical treatment and … services for pharmaceutical and biotechnology customers. To …
-
Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results
03 Mar 2025 21:23 GMT
… BioThrax®, Anthrasil® and Raxibacumab
Smallpox MCM — comprises … overhead and remediation costs related … medical countermeasure ("MCM") products, including CYFENDUS® (Anthrax Vaccine … Drug Product facility in Baltimore-Camden to Bora Pharmaceuticals …
-
Antibiotic Drug Resistance
25 Sep 2019 05:30 GMT
… .7 Glycopeptides Under Clinical Trials 88 4.8 Glycopeptide … of Key and Secondary Drug Resistance Mutations on Structure … References 468 19 Nontraditional Medicines for Treatment of Antibiotic Resistance 477 … 478 19.2.1 Raxibacumab Versus Bacillus anthracis 478 …
-
BioRationality: A Proposal to Create a New Association With Rational Scientific Agenda
18 Nov 2024 14:06 GMT
… ); ipilimumab (2011); pertuzumab (2012-2020); raxibacumab (2012); obinutuzumab (2013); trastuzumab emtansine … for many classes of biological medications remains intact. While scientific literature … FDA that seems to be taking root: to create a biological Drug …
-
Products Approved for Anthrax
23 Oct 2024 16:15 GMT
… (CBER)
Biothrax (Anthrax Vaccine Adsorbed) (CBER)
Ciprofloxacin
Cyfendus (FDA approved 7… G Procaine
Penicillin G Sodium
Raxibacumab
Considerations in Pediatrics, Pregnancy, and …
-
Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
03 Oct 2017 11:00 GMT
… S. Food and Drug Administration (FDA) for the treatment and prophylaxis of … acquisition of raxibacumab expands Emergent’s portfolio of approved medical countermeasures that … Orphan Drug designation in the U.S. Raxibacumab is indicated for the treatment …
-
Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
19 Jul 2017 20:15 GMT
… portfolio of approved medical countermeasures addressing … and Drug Administration (FDA) for the treatment and … our franchise of vaccines and therapeutics … raxibacumab
Raxibacumab is the first monoclonal antibody approved by the FDA for the treatment …
-
Emergent BioSolutions Reports Third Quarter 2024 Financial Results
06 Nov 2024 21:05 GMT
… BioThrax®, Anthrasil® and Raxibacumab
Smallpox MCM — comprises … lower overhead and remediation costs related to … medical countermeasure ("MCM") products, including CYFENDUS® (Anthrax Vaccine … SERB Pharmaceuticals and the sale of our drug product …
About
© 1995-2025